⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
India is facing a silent epidemic of prediabetes. The ICMR-INDIAB study — the largest national diabetes survey ever conducted — found that approximately 136 million Indians have prediabetes as of 2023. The tragedy is that most of them do not know it, are not being treated for it, and will convert to full type 2 diabetes within 5–10 years if nothing changes.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are increasingly being discussed not just as treatments for existing diabetes and obesity — but as tools to prevent the transition from prediabetes to diabetes altogether. This guide explains the evidence, the practical pathway, and the questions to ask your doctor.
Consult your healthcare provider before starting any medication.
Prediabetes is a metabolic state between normal blood sugar and type 2 diabetes. The pancreas is still producing insulin, but the body's cells have become partially resistant to it — requiring more insulin to achieve the same effect. Eventually, the pancreas cannot keep up, and blood sugar rises into the diabetic range.
Prediabetes is diagnosed by any one of three tests:
| Test | Normal | Prediabetes | Type 2 Diabetes |
|---|---|---|---|
| Fasting plasma glucose | Below 100 mg/dL | 100–125 mg/dL | 126+ mg/dL |
| HbA1c | Below 5.7% | 5.7–6.4% | 6.5%+ |
| 2-hr glucose (OGTT) | Below 140 mg/dL | 140–199 mg/dL | 200+ mg/dL |
Important for Indians: Indian bodies develop insulin resistance at lower BMI and waist circumference than Western standards. The WHO recommends using a BMI cutoff of 23 kg/m² (not 25) for overweight in South Asians, and 27.5 for obesity. This means an Indian person at BMI 24 is already in the overweight range and at significantly elevated diabetes risk — even though Western charts would call them "normal weight."
Several factors make Indians particularly prone to prediabetes and rapid progression to type 2:
Genetic predisposition: Indians have significantly lower capacity for beta-cell compensation (the pancreatic response to insulin resistance). Even at lower degrees of insulin resistance, Indian pancreases are more likely to "give up" and let blood sugar rise.
Thin-fat phenotype: Indians store proportionally more fat in visceral (abdominal) and ectopic (liver, muscle, pancreas) locations even at normal body weight. This visceral fat is the primary driver of insulin resistance.
High-carbohydrate diet: The traditional Indian diet — rice, roti, dal, sabzi — is carbohydrate-heavy, with the white rice and maida (refined flour) components causing high glycaemic load.
Sedentary urbanisation: As India urbanised, physical activity dropped sharply. Desk jobs, car commutes, and TV evenings replaced agricultural and manual labour lifestyles.
Early onset: Indians develop type 2 diabetes on average 10 years earlier than Europeans. Prediabetes often begins in the 30s and 40s — decades earlier than Western populations.
GLP-1 receptor agonists address prediabetes through multiple mechanisms simultaneously:
1. Weight reduction: Visceral fat (the primary driver of insulin resistance in Indians) is preferentially reduced by GLP-1 medications. Even a 5–10% reduction in body weight dramatically improves insulin sensitivity.
2. Direct beta-cell protection: GLP-1 receptors are found in pancreatic beta cells. GLP-1 agonists appear to protect beta cells from the glucolipotoxicity (damage from high glucose and fat) that accelerates beta-cell failure in prediabetes.
3. Improved insulin secretion: GLP-1 enhances glucose-dependent insulin secretion — meaning it makes the pancreas more efficient at responding to a carbohydrate meal.
4. Reduced hepatic glucose production: GLP-1 medications reduce the liver's tendency to release excess glucose, a key driver of fasting hyperglycaemia in prediabetes.
5. Appetite and food intake modulation: By reducing appetite and food preference for high-glycaemic foods, GLP-1 medications help patients naturally shift toward a lower-carbohydrate dietary pattern.
The evidence for GLP-1 medications preventing type 2 diabetes is significant and growing.
In the STEP-5 trial, patients with obesity who did NOT have type 2 diabetes were treated with semaglutide 2.4 mg (Wegovy dose) for 104 weeks. Among participants who had prediabetes at baseline:
In SURMOUNT-1, participants with prediabetes at baseline who received tirzepatide 15 mg:
The landmark US Diabetes Prevention Program showed that intensive lifestyle modification reduced diabetes conversion by 58%, and metformin reduced it by 31%. GLP-1 medications appear to outperform both approaches in available data — though head-to-head trials are pending.
Your doctor may consider GLP-1 medications for prediabetes if you have:
High-risk prediabetes indicators:
Metabolic risk factors:
Practical barriers without additional conditions: In India, GLP-1 medications are currently approved by CDSCO for type 2 diabetes and obesity (BMI ≥30, or ≥27.5 with a weight-related comorbidity). For pure prediabetes without obesity or diabetes, off-label use is possible but requires strong clinical justification and private funding. Most insurance plans in India do not currently cover GLP-1 medications.
Guidelines (ICMR, ADA, RSSDI) recommend these steps for prediabetes in order:
Intensive lifestyle modification (ILM): 150+ minutes of moderate exercise per week + dietary changes targeting 5–7% body weight loss. This is the most evidence-based first-line intervention and is free.
Metformin: In high-risk prediabetes (HbA1c 6.0–6.4%, BMI ≥35, history of gestational diabetes), metformin 500–1,000 mg daily is recommended by ADA guidelines. Costs ₹20–60 per month. Highly effective, especially in younger patients.
GLP-1 medications: When lifestyle + metformin fail to normalise blood sugar, or in patients with obesity who need weight loss alongside glucose control.
At your next appointment, ask:
If you are on GLP-1 medications for prediabetes, your doctor should monitor:
| Test | Frequency |
|---|---|
| HbA1c | Every 3 months initially |
| Fasting glucose | Monthly |
| Lipid panel (cholesterol) | Every 6 months |
| Kidney function (eGFR, creatinine) | Every 6 months |
| Liver enzymes (ALT, AST) | Every 6 months |
| Body weight and BMI | Monthly |
| Waist circumference | Every 3 months |
The goal of GLP-1 therapy in prediabetes is not just to lower blood sugar — it is to reverse the underlying metabolic dysfunction. Full remission means:
The STEP-5 and SURMOUNT-1 data suggest this is achievable for a majority of patients who start GLP-1 therapy early and lose significant weight. For an Indian patient at BMI 28 with prediabetes who loses 12–15 kg, the chance of full blood sugar normalisation is substantial.
This makes prediabetes one of the most compelling indications for GLP-1 therapy in the Indian context — a chance to permanently stop the clock on the most common progressive disease in the country.
Consult your healthcare provider before starting any medication.
